Trial results2027a window, not a day
SUSTAIN Phase 3 topline: solriamfetol in shift work disorder
Axsome expects to report results from its Phase 3 study of Solriamfetol (Sunosi) for Shift work disorder during 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
DetailsClinical trial results · also called: readout / topline data
- Company
- Axsome Therapeutics, Inc. AXSM
- Drug
- Solriamfetol (Sunosi)
- For
- Shift work disorder
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- 2027 · the company gave a window, not a day; the calendar never invents one
- Source note
- Company guides topline results from the SUSTAIN Phase 3 trial 'in 2027' (year-level precision only).
- Checked
- Checked by a person when it was added
Check the sourcesdon’t take our word for it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- AXSM headlines on this site
Axsome Therapeutics, Inc.
3 upcoming · 3 past catalysts
More from AXSM
Axsome expects to report results from its Phase 3 study of Solriamfetol (Sunosi) for Binge eating disorder in Q4 2026 (Oct–Dec) (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- ENGAGE Phase 3 topline: solriamfetol in binge eating disorder · Clinical trial results (readout / topline data)
- Drug
- Solriamfetol (Sunosi)
- For
- Binge eating disorder
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- Q2 2026 press release (Aug 10, 2026): 'The Company anticipates topline results from the ENGAGE Phase 3 trial in the fourth quarter of 2026.'
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- AXSM headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page